The Longevity Fund is hosting a casual talk and drinks event this Wednesday, April 10th in Boston. Join to meet and mingle with other researchers and entrepreneur in biotech. Laura Deming, Partner at Longevity, will give a quick Q&A on biotech entrepreneurship. RSVP to firstname.lastname@example.org
The Longevity Fund is a San Francisco-based biotechnology venture capital fund. We invest in and build companies which have the potential to extend the healthy human lifespan. The Longevity Fund closed Fund II in 2017 and launched AGE1, a biotechnology accelerator, in 2018.
We started The Longevity Fund to invest in science to prevent or reverse aging. Our Longevity Fellows program seeks to identify young scientists capable of generating aging’s Apollo or Atari moment: singular accomplishments that made some of humanity’s oldest dreams seem approachable and achievable.
To date, we have raised $37 million, we have been involved in bringing the new science to the market. With our first IPO Unity Biotechnologies, our companies are worth in aggregate of $1.5 billion, with over $500 million raised across them. Four of the five companies in our first portfolio have drugs in patients or healthy volunteers, which will read out in clinical efficacy within the next two years. These represent the first candidate drugs with the explicit possibility of extending healthy lifespan.
Send this to a friend